{"entity":{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","aka":[],"tldr":"A phase 2 trial of Nivolumab in ovarian cancer, run by USWM CT, LLC, active and no longer recruiting.","summary":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) is a phase 2 interventional study registered as NCT05601752 by USWM CT, LLC, with 66 participants planned, started 2023-06-26 and due to reach its primary completion in 2026-08-12. Interventions recorded: Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05601752","url":"https://clinicaltrials.gov/study/NCT05601752"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05601752","phase":"2","setting":"A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers","sponsor":"USWM CT, LLC","enrolled":66,"outcomes":[]},"route":"/trials/nct05601752/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}]}}